Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that the Israel Innovation Authority has approved expanded support for its project to advance a robotic aseptic fill & finish platform. The company can now utilize the full approved grant budget of NIS 5 million over two years, with approximately 66% of that funding being non-dilutive. This decision follows additional review by the authority and reinforces Scinai's commitment to enhancing its sterile biologics manufacturing capabilities.
The program supports the acquisition and validation of a fully automated robotic-arm aseptic fill & finish system aligned with EU GMP Annex 1 standards. Validation is targeted for the third quarter of 2026. The investment is part of Scinai’s broader CDMO expansion strategy, which follows its acquisition of Recipharm Israel Ltd. and a commercial collaboration with Recipharm. This structure strengthens the company’s integrated two-site manufacturing platform and enhances its ability to serve clients requiring sterile biologics, while maintaining disciplined capital allocation through maximized non-dilutive funding.
Scinai Immunotherapeutics operates a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D pipeline. The CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies. It operates two sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne. The CDMO supports external clients from preclinical development through Phase I/II clinical supply, including biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization.
Through a strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm’s global network. This structure enables continuity of development, streamlined tech transfer, and reduced scale-up risk as programs advance. The CDMO unit engages with early-stage and emerging biotech companies and mid-size pharmaceutical companies outsourcing early development programs.
In parallel, Scinai is advancing through its R&D unit a focused immunology pipeline, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation.
For more information, see the full press release at https://ibn.fm/SxadB and the latest news at https://ibn.fm/SCNI.
